ASCO 2019 Abstracts Released: The Myeloma Top 10 

The 2019 American Society of Hematology (ASCO) Annual Meeting in Chicago is fast approaching (May 31-June 4). Out of a total of 4,950 abstracts released Wednesday, May 15, 210 are myeloma related. As usual, there is one oral session on Sunday, June 1 from 9:45 am -12:45 pm, which includes the top eight oral abstracts (numbers 8000 through 8007). I will review these, plus a couple of poster presentations that are worthy of mention (#8015 and #8023) to give my initial Top 10 Abstracts for ASCO 2019.

Myeloma News Roundup: ASCO Abstracts Released, China Meetings Succeed, and iStopMM Clinic Officially Opens

The abstracts for the 2017 ASCO annual meeting, to be in held June 2nd to June 6th in Chicago, were released late yesterday. Among the 84 myeloma and/or amyloid or plasma cell disorders abstracts, there are 10 oral presentations. There are no blockbuster myeloma presentations this year. Most abstracts deal with results with novel combination therapies incorporating, for example, daratumumab (and other anti-CD38 antibodies), checkpoint inhibitors, venetoclax, pomalidomide, and carfilzomib.

The results of the EMN02/HO95 (Hovon) trial for transplant-eligible patients evaluating the role of minimal residual disease (MRD) testing (Abstract #8011) will be presented. The denosumab and Zometa randomized trial dataset presentation will again illustrate the lesser renal toxicities with denosumab (Abstract #8005). An important analysis evaluates cardiovascular toxicities with carfilzomib (Abstract #8018). An interesting study finds that patients with an elevated BMI who have SMM are more likely to progress—important because of potential weight-loss intervention (Abstract #8032). Several studies look at costs. Overall, there are quite a few interesting observations here which are helpful in defining and refining novel agent treatment strategies moving forward.